Kornimate/medical-research-clean huggingface dataset:
outcomes for medicare asthma patients taking fluticasone propionate/salmeterol xinafoate combination versus inhaled corticosteroids or other combination therapy

Conditions: Asthma

Summary: the objective of this study is to compare healthcare utilization and costs in medicare-eligible asthma patients (aged \>65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a typical clinical practice using a retrospective observational cohort study design of large managed care database. outcomes on interest include asthma related severe exacerbations defined as asthma related emergency department visits, hospitalizations or combined emergency department/hospitalization. other outcomes of interest include use of albuterol, oral corticosteroids and overall asthma related costs. outcomes of interest will be compared between the two treatment cohorts (fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids). dichotomous outcomes (emergency visits, hospitalizations etc) will be compared using cox regression hazards analysis assessing time to first event for each asthma related endpoint adjusting for differences in baseline demographics such as age, gender, previous asthma medication use, co morbidities, costs, and plan demographics. total asthma related costs will also be compared using generalized linear models adjusting for baseline differences.


Eligibility criteria:
inclusion criteria: * subjects with asthma as determined by icd-9 codes and asthma drug use * at least 65 years of age * prescription for an inhaled corticosteroid exclusion criteria: * a diagnosis of chronic obstructive pulmonary disease or * a prescription for a chronic obstructive pulmonary disease treatment

Keywords: asthma treatment advair and inhaled corticosteroids medicare outcomes costs
assessment of the effectiveness of local ablathermy radio frequency bronchial tumors primitive

Conditions: Malignant Non-small Cell Neoplasm of Lung Stage Ia

Summary: lung tumors of non-small cell stage 1a are usually treated surgically but many patients are not operable because of their condition or respiratory problems associated with it. the treatment is then suggested that local radiotherapy is conventionally carried out in split mode for 6 weeks at a dose of 60-65 gy irradiation mode this exposes the patient to complications, including post-radiation pneumonitis.

lung tumors of non-small cell stage 1a are usually treated surgically but many patients are not operable because of their condition or respiratory problems associated with it. the treatment is then suggested that local radiotherapy is conventionally carried out in split mode for 6 weeks at a dose of 60-65 gy irradiation mode this exposes the patient to complications, including post-radiation pneumonitis. this can be problematic in patients with respiratory failure for which surgical treatment has been challenged. radiofrequency pulmonary developed as a therapeutic alternative, it has the advantage of being performed in a session with less toxicity in the lung parenchyma

Eligibility criteria:
inclusion criteria : 1. patients over 18 years 2. histological diagnosis of non-small cell lung tumor established. 3. stage 1a tumors (lesions \<= 3 cm, n0) report prepared by pet and ct 4. surgical treatment of the lesion contrindiqué or refused by the patient, 5. arf considered technically feasible after discussing the case in a multidisciplinary meeting (rcp) 6. expectancy greater than 6 months life 7. pet before inclusion (8 weeks maximum before radiofrequency) showing uptake (suv\> = 2.5) at the lesion to be treated, 8. signed informed consent, 9. patient affiliated to a social security scheme. exclusion criteria : 1. location of the lesion does not allow achieving ablathermy under satisfactory conditions: lesion contiguous to the major anatomical structures of the mediastinum, hilar location (less than 1 cm from the hilum) 2. disorder of uncontrolled bleeding (tp \ 1.5 x control). 3. abnormal blood count platelets \<90000/mm3 4. cons-indication to general anesthesia 5. patient with a cardiac pacemaker if a review indicates treatment against arf 6. pregnancy 7. patient included in another clinical study 8. unable to undergo medical monitoring test for geographical, social or psychological reasons, 9. private patient freedom and major subject of a measure of legal protection or unable to consent.

Keywords: malignant non-small cell neoplasm of lung
flexstone enabled kidney stone retrieval

Conditions: Kidney Calculi

Summary: this study investigates if additional basket control in helpful during retrieval of kidney stones especially those that are difficult to reach for standard baskets.

the clinical practice at vanderbilt university medical center will perform standard flexible ureteroscopy (furs) procedures using conventional stone retrieval baskets, the endotheia flexstone basket, laser fibers for intracorporeal lithotripsy , and any other furs accessory devices as determined by the surgeon. if renal calculi are present which the physician deems retrieval of would benefit from the added aimability of the endotheia flexstone basket will be used.

Eligibility criteria:
inclusion criteria: * male or female, 18 to 80 years of age * able to provide written informed consent * have renal stones present and are appropriate candidates for furs exclusion criteria: * females who are pregnant. as part of routine pre-operative care, all females of childbearing potential will undergo either urine or blood pregnancy testing. * cancer positive subjects or any patients currently undergoing any treatment or therapy to treat, cure, or mitigate cancer. * patients with active urinary tract infection or anatomy that complicates retrograde access to the ureter and kidney * patients who do not meet inclusion criteria * patients who are unable or unwilling to provide informed consent
effects of ciprofol anesthesia on learning and memory function and antidepressant effects of ect in depressive patients

Conditions: Depressive Disorder

Summary: in this clinical study, propofol was used as the positive control, and a randomized controlled trial design was used to observe the effects of ciprofol anesthesia on learning and memory function and antidepressant efficacy in patients with ect. a total of 390 depressed patients who were to undergo electroconvulsive therapy were selected and randomly divided into two groups, namely the propofol group (n=195 cases) and the ciprofol group (n=195 cases). the patients in the propofol group were given propofol 1.5mg/kg + succinylcholine 1mg/kg, and the patients in the ciprofol group were given ciprofol 0.4mg/kg and succinylcholine 1mg/kg, and the patients were given electroshock after anesthesia treat.

ciprofol injection, whose active component (hsk3486) is propofol analogue, is a novel treatment for anesthesia induction and maintenance. it has been authorized for commercialization in china on december 14, 2020. the purpose of this experiment is to know the effect of ciprofol on the antidepressant effect and cognitive function of depressive patients after electroconvulsive therapy. ciprofol is very similar in structure to propofol, so propofol was used as the control group in this experiment.

Eligibility criteria:
inclusion criteria: 1. depressed patients who plan to receive mect. 2. meet the diagnostic criteria of dsm-iv depression 3. 16≤age≤45 years old, gender is not limited 4. asa score is i or ii 5. the depressive episode lasted for at least 2 weeks 6. clearly understand and voluntarily participate in the study and sign the informed consent form. exclusion criteria: 1. combined with serious physical diseases, such as uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, asthma attacks, severe liver and kidney dysfunction, etc. 2. foreign bodies in the body: such as pacemakers, intracranial electrodes, etc. 3. those who have a history of epilepsy 4. those who are taking reserpine 5. those with acute and systemic infectious diseases, with moderate or higher fever 6. those with a history of manic episodes 7. those with anesthetics, allergic to muscle relaxants 8. pregnant women 9. glaucoma 10. bipolar disorder, or combined with other mental illnesses, mental retardation 11. those who are judged not suitable for mect treatment by the competent physician 12. history of drug abuse
osmotic therapy for patients with severe subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage, Traumatic

Summary: the goal of this prospective multi-center observational study is to learn about the osmotic therapy in severe subarachnoid hemorrhage (sah). the main question\[s\] it aims to answer are: • whether the two osmotic therapy, 20% mannitol and 10% hypertonic saline(hts), under the same osmotic equivalent, has similar influence on the outcome of sah patients? participants will be given proper treatment according to local expert consensus, including the choice of osmotic medicine. investigators just record and analyse the data, compare mannitol group and hts group to see if the outcome of latter is not worse than the former.


Eligibility criteria:
inclusion criteria: * ①age ≥18； ②aneurysmal subarachnoid hemorrhage; ③hunt-hess 3-5级 exclusion criteria: * previous cranial decompression surgery, cerebrospinal fluid leakage or drainage, * bilateral pupils fixed or dilated, * hemodynamic instability, * hemoglobin \< 8g / l, * serum osmolality \> 320 mosm / l, ⑥ combined with severe organ dysfunction (cardiac, pulmonary, hepatic, renal and so on); ⑦ serious electrolyte disorders (serum sodium concentration \ 170 mmol / l), and difficult to correct within limited time; ⑧ serious acid-base balance disorders, and difficult to correct within limited time; ⑨ use of mannitol or hss within previous six hours; ⑩ being pregnant.

Keywords: subarachnoid hemorrhage, mannitol, hypertonic saline, outcome
stroke and assessment of muscle tone

Conditions: Stroke; Muscle Tone Abnormalities; Pain; Muscle Spasticity

Summary: spasticity is defined as a state of increased muscle tone, which evokes an increased resistance to a passive and fast stretching of the muscle. indeed, the degree of spasticity depends, among other things, on the stretching velocity performed to the muscle. however, most of the tools used in the clinical setting to assess spasticity do not take into account the relationship between increased muscle tone and speed of stretching. instead of that, muscle tone is usually assessed in a relaxed position of the muscle. likewise, to date, despite the functional disabilities related to the presence of chronic pain after a stroke, no previous study has correlated muscle tone and pressure pain sensitivity within this population


Eligibility criteria:
inclusion criteria: * be older than 18 years * clinical diagnosis of stroke, confirmed using a mri. * no previous history of other strokes. * increases muscle tone in upper and lower extremities (punctuation equal to or superior to 1 in the tardieu scale, ashworth scale) * ability to understand the study goals, follow simple instructions and provide informed consent. * score equal to or superior to 24 in the minimental state examination. exclusion criteria: * any other confirmed neurological disorder that may influence muscle tone (multiple sclerosis, parkinson, muscle dystrophies...) * a chronic musculoskeletal disorder in the upper or lower limb. * previous history of surgery in the upper or lower extremities. * changes in the medication intake that may affect muscle tone assessments in the 48 hours before data collection. * having received botulin toxin in gastrocnemius or biceps brachii muscles in the 30 days before data collection. * a concomitant acute infection during data collection. * a previous epileptic crisis in the week before the study or during the study.

Keywords: topographical mapping muscle state of tension myotonometer pressure pain threshold muscle thickness
pharmacokinetic study of pediatric subjects with tinea cruris and tinea pedis

Conditions: Tinea Pedis; Tinea Cruris

Summary: this study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. safety of the drug and how well the drug works will also be measured.

study population, diagnosis, and main criteria for inclusion: tinea pedis and tinea cruris (naft-500): male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with tinea pedis and tinea cruris infections confirmed by a positive potassium hydroxide (koh) analysis from both the feet and bikini area. both cases (feet and bikini area) must be characterized by clinical evidence of a tinea pedis and tinea cruris infection. additional, approximately 4 pharmacokinetic (pk) evaluable adult subjects with the same condition will serve as a control. tinea pedis (naft-600): male or non-pregnant female subjects aged 12 to 17 years, 11 months old of any race with tinea pedis infection confirmed by a positive potassium hydroxide (koh) analysis from both feet. both feet must be characterized by clinical evidence of a tinea pedis infection. additional, approximately 4 pharmacokinetic (pk) evaluable adult subjects with the same condition will serve as a control.

Eligibility criteria:
inclusion criteria: * subjects must have tinea pedis on both feet and tinea cruris infections for naft-500; both conditions must be characterized by clinical evidence of a tinea infection. * subjects must have tinea pedis on both feet for naft-600; the condition must be characterized by clinical evidence of a tinea infection. exclusion criteria: * a known hypersensitivity to study medications or their components * any severe condition of tinea pedis (incapacitating) * any dermatological disease and or condition in the treatment or surrounding area that may prevent application of the study product such as foot psoriasis, corns and /or callus involving any web spaces, or atopic or contact dermatitis * positive pregnancy test * any history or current evidence (physical or laboratory) of anemia

Keywords: tinea pedis tinea cruris athlete foot jock itch
evaluate the safety and efficacy of naftifine hydrochloride cream 2% and naftin® cream 2% in patients with tinea pedis

Conditions: Tinea Pedis

Summary: the objective of this study is to compare the efficacy and safety of the test formulation of naftifine hydrochloride cream 2% to naftin® (naftifine hydrochloride) 2% cream in a 6 week study in patients with tinea pedis.


Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating females 18 years or older * clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot * the presence of interdigital tinea pedis infection * the sum of the clinical signs and symptoms scores of the target lesion is at least 4, including a minimum score of at least 2 for erythema and a minimum score of 2 for either scaling or pruritus exclusion criteria: * females who are pregnant, lactating or planning to become pregnant during the study period * use of antipruritics, including antihistamines within 72 hours prior to baseline visit * use of topical corticosteroids, antibiotics or antifungal therapies within two weeks prior to baseline visit * use of systemic corticosteroids, antibiotics or antifungal therapies within one month prior to baseline visit * use of oral terbinafine or itraconazole within two months prior to baseline visit * use of immunosuppressive medication or radiation therapy within three months prior to baseline visit * any known hypersensitivity to naftifine hydrochloride, or any component of the formulation * confluent, diffuse moccasin-type tinea pedis of the entire plantar surface * history of significant or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that would place undue risk by participation or could jeopardize the integrity of study evaluations * evidence of any concurrent dermatophytic infection of the toe nails or dermatological condition of the foot that may interfere with tinea pedis evaluation * past history of dermatophyte infections with a lack of response ot antifungal therapy

Keywords: naftifine naftin® tinea pedis
effect of spirulina on liver iron concentration in beta thalassemic children with hepatitis c

Conditions: Beta Thalassemia Major

Summary: thalassemics can develop liver fibrosis because of iron overload and hepatitis c infection. the latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics. excess liver iron is clearly recognized as a co factor for the development of advanced fibrosis in patients with hepatitis virus c infection. magnetic resonance imaging represents the most available noninvasive technique to assess the level of iron in the liver.there is evidence that suggests spirulina may help to protect against liver damage, cirrhosis and liver failure in those with chronic liver disease.


Eligibility criteria:
inclusion criteria: * multitransfused beta thalassemic children with super added hepatitis c virus (hcv) infection diagnosed by serological detection of hcv antibodies and hcv rna by polymerase chain reaction. exclusion criteria: * liver decompensation child younger than 3 years patients with hepatitis b infection contraindications to perform mri (intraocular metallic foreign body, cardiac pacemaker, intracranial clips of arterial brain aneurysms) refusal to participate in the study
anesthesia in flexible bronchoscopy for lung cancer diagnostic

Conditions: Lung Cancer

Summary: the objective of the study was to establish which anesthetic procedure used during flexible bronchoscopy has the lowest index of complications.

this prospective randomized study analyzed 80 patients that underwent flexible bronchoscopy. patients were randomly assigned to four groups of 20 patients each according to the anesthetic combination used: 200 mg topical lidocaine (lid group); 200 mg topical lidocaine and 2 mg/kg propofol (ppf group); 200 mg topical lidocaine and 20 mcg/kg alfentanil (alf group); or 200 mg topical lidocaine and 0.05 mg/kg midazolam (mid group). scores were assigned to patients according to the different variables observed during the endoscopic procedure; the lower the score, the lower the complication index.

Eligibility criteria:
inclusion criteria: * the patients included in this study were referred to fbc for the investigation of bronchial carcinoma (diagnostic procedure). * patients included in the study were classified as asa i, ii and ii according to the anesthetic risk classification of the american society of anesthesiologists (asa). exclusion criteria: * asa iv classification of anesthesiology risk * procedure that lasted longer than 15 minutes * indication of therapeutic bronchoscopy * cardiac arrhythmia and / or hypoxemia detected at admission.

Keywords: alfentanil anesthesia bronchoscopy lidocaine midazolam propofol.
pain in endometriosis and the relation to lifestyle

Conditions: Endometriosis; Adenomyosis

Summary: the goal of this clinical trial is to investigate the effect of an anti-inflammatory diet and cognitive behavioral therapy (cbt) on pain symptoms, health related quality of life and the effect on inflammatory characteristics in serum and menstruum samples as well as the effect on the gut and vaginal microbiome in women with endometriosis. participants will be randomized between standard care (control group), standard care and an anti-inflammatory diet, or standard care, anti-inflammatory diet and cognitive behavioral therapy or cbt alone. participants will follow an anti-inflammatory diet based on the dutch dietary guidelines or cbt or a combination of both interventions for 12 weeks. they will receive personalized dietary advice from a dietician and recipes will be available. cognitive behavioral therapy will be administered in a total of seven individual sessions led by a psychotherapist. the content of these sessions will be psycho-education regarding pain mechanisms and diet.


Eligibility criteria:
inclusion criteria: * age from 17 years * premenopausal status * body mass index (bmi) 18-30 kg/m2 * ability to understand the explanation about the diet intervention (di) and cbt * willing to follow the di * willing to continue their use of food supplements * willing to undergo cbt * willing to collect menstrual effluent, and therefore willing to have two stop weeks from hormonal contraception (if applicable) during the study period. exclusion criteria: * recurrent miscarriages (\> 2) * eating disorder * diagnosed with crohn's disease, ulcerative colitis, short bowel syndrome or another chronic inflammatory disease * self-reported celiac disease * vegan diet * smoking * use of immunosuppressive or psychotropic medication * score on ffq \> 120 * diagnosed with severe mental disorder currently requiring treatment by psychiatrist * nrs average score below 4 during the last month * participation in another intervention study * unable to speak dutch or to understand the intervention * need for surgery during the participation in the study * serious pain (nrs \> 4) from other origin than endometriosis * pregnant * scalp hair shorter than 4 cm

Keywords: endometriosis pain quality of life immunology anti-inflammatory diet cognitive behavioral therapy adenomyosis
a study to assess the safety and tolerability of asp1941 in adults with type 2 diabetes mellitus.

Conditions: Diabetes Mellitus, Type 2

Summary: this study is intended to assess safety and tolerability of asp1941 compared to placebo in adult subjects with type 2 diabetes mellitus

trial includes a two week washout period before entering the treatment period for subjects on oral anti-diabetic medication.

Eligibility criteria:
inclusion criteria: * established diagnosis of type 2 diabetes mellitus * hba1c value between 7.0 and 10.0% * body mass index between 20 and 45 kg/m2 exclusion criteria: * established diagnosis of type 1 diabetes mellitus * serum creatinine \> upper limit of normal range * proteinuria (microalbumin/creatinine ratio \> 300 mg/g) * urinary tract infection * severe uncontrolled hypertension * significant renal, hepatic or cardiovascular disease * hiv positive * history of drug or alcohol abuse/dependency

Keywords: asp1941 type 2 diabetes mellitus